NCT00873210
Completed
Not Applicable
Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With Sutent
Overview
- Phase
- Not Applicable
- Intervention
- Sutent
- Conditions
- Advanced or Metastatic Renal Cell Carcinoma
- Sponsor
- Pfizer
- Enrollment
- 121
- Locations
- 1
- Primary Endpoint
- Increased knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.
Detailed Description
Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
Investigators
Eligibility Criteria
Inclusion Criteria
- •Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
Exclusion Criteria
- •Hypersensitivity to sunitinib malate or to any of the excipients
- •Any other contraindication to the use of sunitinib malate (based on decision of the treating physician).
Arms & Interventions
Patients treated with Sutent
125 consecutive patients in outpatient care with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
Intervention: Sutent
Outcomes
Primary Outcomes
Increased knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib
Time Frame: 36 months
Secondary Outcomes
- Dose modifications(36 months)
- Incidence of new diagnosed hypertension(36 months)
- Incidence of new diagnosed hypothyroidism(36 months)
- Safety of sunitinib malate in "real-life" setting(36 months)
- Efficacy of sunitinib malate in "real-life" setting(36 months)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®Metastatic Renal Cell CarcinomaNCT00684645Pfizer186
Completed
Not Applicable
Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor TherapyBreast NeoplasmsNCT00784888Pfizer344
Completed
Not Applicable
Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular DegenerationMacular DegenerationAge-related Macular DegenerationNeovascular Macular DegenerationNCT01245387Pfizer1,001
Completed
Not Applicable
Evaluation of Safety of ZyComb® In Patients With Common Cold - ZIP 3000 (XY-005-IM)Common ColdNCT00480194Nycomed1,000
Completed
Not Applicable
Health-related Quality of Life in Patients on AnticoagulantsAtrial FibrillationNCT03134911Boehringer Ingelheim535